The Tumorigenic Potential of Human Pluripotent Stem Cells

Elyad Lezmi, Nissim Benvenisty*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Human pluripotent stem cells (hPSCs) are currently evaluated for clinical applications due to their proliferation and differentiation capacities, raising the need to both assess and enhance, the safety of hPSC-based treatments. Distinct molecular features contribute to the tumorigenicity of hPSCs, manifested in the formation of teratoma tumors upon transplantation in vivo. Prolonged in vitro culturing of hPSCs can enhance selection for specific genetic aberrations, either at the chromosome or gene level. Some of these aberrations are tightly linked to human tumor pathology and increase the tumorigenic aggressiveness of the abnormal cells. In this perspective, we describe major tumor-Associated risk factors entailed in hPSC-based therapy, and present precautionary and safety measures relevant for the development and application of such therapies.

Original languageAmerican English
Pages (from-to)791-796
Number of pages6
JournalStem cells translational medicine
Issue number8
StatePublished - Aug 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press.


  • aneuploidy
  • cancer-related mutations
  • human pluripotent stem cells
  • teratocarcinoma
  • teratoma
  • tumorigenicity


Dive into the research topics of 'The Tumorigenic Potential of Human Pluripotent Stem Cells'. Together they form a unique fingerprint.

Cite this